iShares 3 7 Year Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.57, while GeneDx Holdings Corp trades at $60.81 (market cap $1.80B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | WGS | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $120.72 | $167.51 |
52-Week Low | $116.45 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal. Recent dividends include $0.36 and $0.37 payouts in mid-2026. The ETF faces headwinds from rising Treasury yields and Federal Reserve uncertainty, as bond markets react to inflation and geopolitical tensions.
Outlook remains cautious due to interest rate sensitivity; opportunities exist for low-volatility Treasury exposure, but risks include further Fed hikes and competitive pressure from higher-yielding bond ETFs like Vanguard's offerings.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →